Search Medical Condition
Please enter condition
Please choose location from dropdown

Skoevde, Sweden Clinical Trials

A listing of Skoevde, Sweden clinical trials actively recruiting patients volunteers.

RESULTS

Found (16) clinical trials

Modufolin in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer

The study will investigate the tolerability of Modufolin at four (4) different dose levels (30 to 240 mg/m2) in therapy combinations with the chemotherapeutic agents 5-FU, Oxaliplatin +/- bevcizumab, and Irinotecan. When the selected phase 2 dose is determined, 20 additional patients, will be included in the study in order ...

Phase

0.0 miles

Learn More »

A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.

Phase N/A

0.0 miles

Learn More »

Prospective Single-arm Multi Centre Observations Ultimaster Des Registry

All consecutive patients suitable for treatment with DES according to hospital routine practice in centres across the world that agree to participate in the e-ULTIMASTER registry will be treated with Ultimaster DES. Secondary objectives Evaluation of worldwide utilization of DES, Detection of rare events in representative patient population, identification of ...

Phase N/A

0.0 miles

Learn More »

Swedish Iodine in Pregnancy and Development in Children (SWIDDICH) Study

AIMS To determine if children exposed to mild iodine deficiency (ID) during fetal life achieve worse cognitive development compared to children exposed to normal iodine status reached by maternal iodine supplementation. To compare urinary iodine concentration (UIC), thyroglobulin (Tg), free tetraiodothyronine (FT4) and thyroid stimulating hormone (TSH) in pregnant women ...

Phase N/A

0.0 miles

Learn More »

Sentinel Node Biopsy in Breast Cancner: Omission of Axillary Clearance After Micrometastasis

From April 2017 onwards, only patients operated by mastectomy or those receiving neoadjuvant therapy and having a sentinel node biopsy before its initiation may be recruited into SENOMIC. The inclusion target has been met for those patients operated by breast-conserving therapy, and from now on, these patients will not be ...

Phase N/A

0.0 miles

Learn More »

The Product Surveillance Registry REVERSE Post Approval Study

The REVERSE PAS will estimate the 3-year survival probability of freedom from heart failure hospitalization and heart failure events in patients implanted with a Medtronic CRT-D device who meet the expanded indication criteria with a QRS duration 150 ms.

Phase N/A

0.0 miles

Learn More »

Tenecteplase in Wake-up Ischaemic Stroke Trial

Background One in five strokes occur during sleep, but patients with "wake-up" stroke are not given thrombolytic therapy because time of stroke onset is unknown. On-going trials are testing alteplase, and use MRI techniques for selection of patients. Tenecteplase has many pharmacological advantages over alteplase: greater fibrin specificity, very rapid ...

Phase

0.0 miles

Learn More »

A Randomized Trial to Assess the Role of Imaging During Follow up After Radical Surgery of High Risk Melanoma

The patients are randomized 1:1 to routine follow up for 3 years with regular doctors appointments according to national guidelines and the same follow up but with the addition of whole body CT or Positron Emission Tomography (PET) scans and blood tests.

Phase N/A

0.0 miles

Learn More »

TIMING of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atrial Fibrillation

Oral anticoagulation therapy is well established and highly recommended for the prevention of recurrent ischemic stroke in patients with atrial fibrillation, but the optimal time point to start after an acute ischemic stroke is not known. The intervention in this study will be timing of treatment onset. The choice of ...

Phase N/A

0.0 miles

Learn More »